A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021
COVID-19 has led to a major worldwide health and economic crisis, with more than 27 million people having contracted the disease and more than 800 000 deaths. Objectives – to study the effects of repurposed therapeutics such as ivermectin/favipiravir with or without steroids in clinical outcomes of...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
The Publishing House Medicine and Enlightenment
2023-12-01
|
Series: | Medicina v Kuzbasse |
Subjects: | |
Online Access: | https://mednauki.ru/index.php/MK/article/view/1002 |
_version_ | 1797353491947061248 |
---|---|
author | Srinivasa Jayachandra Sadhana Sonti Vijaya Vathsa C.M.A. Beliappa Praneetha Achanta |
author_facet | Srinivasa Jayachandra Sadhana Sonti Vijaya Vathsa C.M.A. Beliappa Praneetha Achanta |
author_sort | Srinivasa Jayachandra |
collection | DOAJ |
description | COVID-19 has led to a major worldwide health and economic crisis, with more than 27 million people having contracted the disease and more than 800 000 deaths.
Objectives – to study the effects of repurposed therapeutics such as ivermectin/favipiravir with or without steroids in clinical outcomes of mild to moderately severe COVID-19 disease in India.
Methods. 99 nonhospitalized patients with mild to moderate symptomatic COVID-19 who received repurposed drugs like ivermectin or favipiravir or both with or without steroids were included 3 groups of patients were formed. The clinical outcome like oxygen saturation, hospitalization, recovery time, mortality, side effects or complications within 2 weeks after treatment were analyzed. Retrospective data analysis done by appropriate statistical tests using SPSS statistical package version 23.
Results. Ivermectin or favipiravir, independently had no effect on clinical outcome (18/99, 25/99 patients respectively), whereas ivermectin plus favipiravir in combination positively affected recovery time to less than or equal to 4 days (56/99 patients). However ivermectin plus favipiravir plus steroids (51/99 patients) showed a positive effect in terms of recovery time. Patients recovered in 4 days or less.
Conclusion. This study demonstrated the relative safety and efficacy of ivermectin and favipiravir including steroids when appropriately monitored/tailored in managing mild to moderate COVID-19 patients. |
first_indexed | 2024-03-08T13:31:50Z |
format | Article |
id | doaj.art-c2819096d9e44ac19f68a1b25797e480 |
institution | Directory Open Access Journal |
issn | 1819-0901 2588-0411 |
language | Russian |
last_indexed | 2024-03-08T13:31:50Z |
publishDate | 2023-12-01 |
publisher | The Publishing House Medicine and Enlightenment |
record_format | Article |
series | Medicina v Kuzbasse |
spelling | doaj.art-c2819096d9e44ac19f68a1b25797e4802024-01-17T08:28:25ZrusThe Publishing House Medicine and EnlightenmentMedicina v Kuzbasse1819-09012588-04112023-12-012243847871A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021Srinivasa Jayachandra0Sadhana Sonti1Vijaya Vathsa2C.M.A. Beliappa3Praneetha Achanta4Zydus Medical college and Hospital Dahod, GujaratKaiser Permanente, CaliforniaRxDx Healthcare, BangaloreRxDx Healthcare, BangaloreMedical gradate, TexasCOVID-19 has led to a major worldwide health and economic crisis, with more than 27 million people having contracted the disease and more than 800 000 deaths. Objectives – to study the effects of repurposed therapeutics such as ivermectin/favipiravir with or without steroids in clinical outcomes of mild to moderately severe COVID-19 disease in India. Methods. 99 nonhospitalized patients with mild to moderate symptomatic COVID-19 who received repurposed drugs like ivermectin or favipiravir or both with or without steroids were included 3 groups of patients were formed. The clinical outcome like oxygen saturation, hospitalization, recovery time, mortality, side effects or complications within 2 weeks after treatment were analyzed. Retrospective data analysis done by appropriate statistical tests using SPSS statistical package version 23. Results. Ivermectin or favipiravir, independently had no effect on clinical outcome (18/99, 25/99 patients respectively), whereas ivermectin plus favipiravir in combination positively affected recovery time to less than or equal to 4 days (56/99 patients). However ivermectin plus favipiravir plus steroids (51/99 patients) showed a positive effect in terms of recovery time. Patients recovered in 4 days or less. Conclusion. This study demonstrated the relative safety and efficacy of ivermectin and favipiravir including steroids when appropriately monitored/tailored in managing mild to moderate COVID-19 patients.https://mednauki.ru/index.php/MK/article/view/1002covid-19стероидыивермектинфавипиравир |
spellingShingle | Srinivasa Jayachandra Sadhana Sonti Vijaya Vathsa C.M.A. Beliappa Praneetha Achanta A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021 Medicina v Kuzbasse covid-19 стероиды ивермектин фавипиравир |
title | A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021 |
title_full | A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021 |
title_fullStr | A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021 |
title_full_unstemmed | A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021 |
title_short | A RETROSPECTIVE ANALYSIS OF REPURPOSED THERAPEUTICS USED DURING THE DELTA VARIANT INDUCED COVID-19 CRISIS OF INDIA, 2021 |
title_sort | retrospective analysis of repurposed therapeutics used during the delta variant induced covid 19 crisis of india 2021 |
topic | covid-19 стероиды ивермектин фавипиравир |
url | https://mednauki.ru/index.php/MK/article/view/1002 |
work_keys_str_mv | AT srinivasajayachandra aretrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT sadhanasonti aretrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT vijayavathsa aretrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT cmabeliappa aretrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT praneethaachanta aretrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT srinivasajayachandra retrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT sadhanasonti retrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT vijayavathsa retrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT cmabeliappa retrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 AT praneethaachanta retrospectiveanalysisofrepurposedtherapeuticsusedduringthedeltavariantinducedcovid19crisisofindia2021 |